ArticleAnnals of hematology2025
Development and validation of deep vein thrombosis diagnostic model based on machine learning methods.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LncRNA PVT1 targets miR-143-3p to modulate endothelial cell function and thereby participate in deep vein thrombosis (DVT) of the lower limbs.Annals of hematology · 2026Article
- Integrated multi-omics and machine learning identify an interaction between SLC39A11 and phosphoinositide metabolism in deep vein thrombosis.BMC medical informatics and decision making · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The D-Dimer testing has limited diagnostic value for patients with a deep venous thrombosis (DVT) probability based on clinical prediction rules. There are still patients with normal D-Dimer levels (< 500 ng/mL) diagnosed with DVT. Some new predictive marker may improve the predictive power of D-Dimer, especially in DVT patients with normal levels of D-Dimer. All subjects were from Nanyang Central Hospital. The demographic data and laboratory test data were collected. Multiple models were used to evaluate and calculate the importance rank. Multivariate logistics was used to establish a DVT diagnostic model. Compared to D-Dimer and other markers, this combined model has better performance. The von Willebrand factor Gain-of-function mutant GPIb binding assays (VWF: GPIbM) can improve the diagnostic capability of D-Dimer, which has higher diagnostic value and clinical benefits. In addition, the model still has good diagnostic capability in DVT patients with normal D-Dimer levels. The combined model has better diagnostic performance than D-Dimer, and it is valuable for some patients whose clinical prediction rules cannot be evaluated due to difficulties in obtaining medical history information. VWF: GPIbM can be used to assist in the diagnosis of DVT in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.